UNASSIGNED: To systematically evaluate the relationship between the expression level of long noncoding RNA NEAT1 and the clinical characteristics and prognostic value of rectal cancer patients.
UNASSIGNED: PubMed, EMBASE, Cochrane library database and case-control studies on the correlation between abnormal expression of lncRNA NEAT1 and prognosis of rectal cancer patients published by the American clinical trials registry before May 1, 2023 were searched. The search time was from the establishment of the database to May 30, 2023.
UNASSIGNED: A total of 7 case-control studies were included, including 1063 cancer patients. The results of meta-analysis showed that the high expression of lncRNA NEAT1 was significantly correlated with the degree of differentiation [or=0.45, 95%CI=0.32-0.63, P<0.01], tumor size [or=0.59, 95%CI=0.42-0.82, P<0.01], and overall survival [HR=1.34, 95%CI=1.21-1.48, P<0.001]; However, it was not associated with gender [or=1.23, 95%CI= 0.88-1.72, P=0.23] and lymph node metastasis [or=0.87, 95%CI=0.45-1.66, P=0.67].
UNASSIGNED: The high expression of lncRNA NEAT1 may be a risk factor for poor prognosis in patients with malignant tumors, and lncRNA NEAT1 can be used as a potential biomarker to evaluate its prognosis.
UNASSIGNED: Cilj je bio da se sistematski proceni odnos između nivoa ekspresije duge nekodirajuće RNK NEAT1 i kliničkih karakteristika i prognostičke vrednosti pacijenata sa rakom rektuma.
UNASSIGNED: Pretražene su PubMed, EMBASE, Cochrane bibliotečka baza podataka i studije slučaja-kontrole o korelaciji između abnormalne ekspresije lncRNA NEAT1 i prognoze pacijenata sa rakom rektuma koje je objavio američki registar kliničkih ispitivanja pre 1. maja 2023. godine. Vreme pretrage je bilo od uspostavljanja baze podataka do 30. maja 2023. godine.
UNASSIGNED: Uključeno je ukupno 7 studija slučaj-kontrola, uključujući 1063 pacijenata sa rakom. Rezultati meta-analize su pokazali da je visoka ekspresija lncRNA NEAT1 u značajnoj korelaciji sa stepenom diferencijacije [or=0,45, 95%CI=0,32-0,63, P<0,01], veličinom tumora [ili=0,59, 95%CI=0,42-0,82, P<0,01] i ukupno preživljavanje [HR=1,34, 95% CI=1,21-1,48, P<0,001]; Međutim, nije bilo povezano sa polom [ili=1,23, 95%CI=0,88-1,72, P=0,23] i metastazama u limfnim čvorovima [ili=0,87, 95% CI =0,45-1,66, P=0,67].
UNASSIGNED: Visoka ekspresija lncRNA NEAT1 može biti faktor rizika za lošu prognozu kod pacijenata sa malignim tumorima, a lncRNA NEAT1 se može koristiti kao potencijalni biomarker za procenu njegove prognoze.